Traffic Lights - Latest Updates

Last updated: 16/11/2016

Other updates on this site
Drug Name Classification Clinical Indication Comments
ADALIMUMAB Red Hidradenitis suppurativa

In line with NICE TA 392

ALIROCUMAB Subcutaneous Injection (Praluent®) (UPDATED) Red Primary hypercholesterolaemia

In line with NICE TA 393

ALPROSTADIL cream (Vitaros®) (UPDATED) Black Erectile dysfunction
ATALUREN (NEW) Red Duchenne muscular dystrophy

In line with NICE HST3

BRIVARACETAM (NEW) Red Epilepsy (third line agent)
DULAGLUTIDE (UPDATED) Amber Simple Type 2 Diabetes

If prescriber has not received specific training.

DULAGLUTIDE (UPDATED) Green Conditional Type 2 diabetes

Conditional on prescriber being trained to select and train patients – use in conjunction with updated NICE Clinical Guideline.  Once a week preparation.

IMIQUIMOD cream 5% (Aldara®) (NEW) Green Actinic keratoses

In line with Actinic Keratoses treatment pathway

INGENOL MEBUTATE GEL (Picato®) (UPDATED) Green Actinic keratosis (non hypertrophic)

Actinic Keratoses (AK) Treatment Pathway

SACUBITRIL / VALSARTAN (Entresto®) (UPDATED) Amber Full SCA Heart failure

Full SCA    Request form

Other Updates on this Website

Recent documents from LMSG and TAS

About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more